SCHEMBL7607616

SCHEMBL7607616

C[C@@H](O)[C@H](NC1CCCCC1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.50
ALDH1A1 P00352 3/20 0.50
DPP4 P27487 1/20 0.43
ATM Q13315 1/20 0.42
EPHX2 P34913 3/20 0.40
EPHX1 P07099 9/20 0.40
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21518541 0.90 L3MBTL1 (0.43) SMN1; SMN2ALDH1A1DPP4EPHX2NPSR1
SCHEMBL7390148 0.86 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1DPP4ATMEPHX2
SCHEMBL7390156 0.86 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1DPP4ATMEPHX2
SCHEMBL4421612 0.83 DPP4 (0.42) SMN1; SMN2ALDH1A1DPP4ATMEPHX2
SCHEMBL17307367 0.82 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1DPP4ATMEPHX2
SCHEMBL15049761 0.80 L3MBTL1 (0.55) SMN1; SMN2ALDH1A1DPP4ATMEPHX2
SCHEMBL15049760 0.80 L3MBTL1 (0.55) SMN1; SMN2ALDH1A1DPP4ATMEPHX2
SCHEMBL38557 0.78 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1ATMEPHX2EPHX1
SCHEMBL16635360 0.78 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1ATMEPHX2EPHX1
SCHEMBL38558 0.78 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1ATMEPHX2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020168337-A1 Sustained-release preparation TAKADA CHEMICAL INDUSTRIES LTD. 2002-11-14 US disclosed
US-20020058622-A1 Sustained-release preparation IGARI YASUTAKA (JP) 2002-05-16 US disclosed
US-6376461-B1 WATER INSOLUBLE OR SLIGHTLY WATER SOLUBLE POLYVALENT METAL SALT OF A GROWTH HORMONE, AND A BIODEGRADABLE POLYMER; ENDOTHELIN ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-04-23 US disclosed
US-6087324-A A WATER-INSOLUBLE OR A SLIGHTLY WATER-SOLUBLE POLYVALENT METAL SALT OF A WATER-SOLUBLE PHYSIOGICALLY ACTIVE PEPTIDE WHICH IS NOT AN ENDOTHELIN ANTAGONIST, AND A BIODEGRADABLE POLYMER SUCH AS COPOLYMER OF GLYCOLIC AND LACTIC ACID TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-07-11 US disclosed
EP-0647449-A1 Sustained-release preparation of anti-endothelin substance Takeda Chemical Industries, Ltd. (JP) 1995-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020168337-A1 Sustained-release preparation EDNRA, EDNRB, ORAI1 SMN1; SMN2 260/4885ALDH1A1 2741/4885DPP4 2524/4885
US-20020058622-A1 Sustained-release preparation EDNRA, EDNRB, ORAI1 SMN1; SMN2 260/4885ALDH1A1 2741/4885DPP4 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.